Matthieu de Kalbermatten, CellProthera CEO

Scoop: Cell­Prothera eyes $30M round for PhI­II tri­al of cell ther­a­py for heart at­tacks: #Jef­feries23

Cell­Prothera plans to raise around $30 mil­lion in its first ma­jor fundraise to help ad­vance its lead re­gen­er­a­tive cell ther­a­py pro­gram for pa­tients who have …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.